Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Change in Receivables (2016 - 2017)

Historic Change in Receivables for Gsk (GLAXF) over the last 9 years, with Q4 2017 value amounting to -$381.0 million.

  • Gsk's Change in Receivables fell 6302.86% to -$381.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $83.7 million, marking a year-over-year decrease of 8293.47%. This contributed to the annual value of -$573.0 million for FY2018, which is 5496.85% down from last year.
  • Latest data reveals that Gsk reported Change in Receivables of -$381.0 million as of Q4 2017, which was down 6302.86% from -$233.7 million recorded in Q4 2016.
  • Gsk's 5-year Change in Receivables high stood at $549.8 million for Q4 2014, and its period low was -$381.0 million during Q4 2017.
  • Moreover, its 5-year median value for Change in Receivables was $25.9 million (2013), whereas its average is $21.9 million.
  • Per our database at Business Quant, Gsk's Change in Receivables skyrocketed by 202230.9% in 2014 and then tumbled by 25716.45% in 2016.
  • Gsk's Change in Receivables (Quarter) stood at $25.9 million in 2013, then skyrocketed by 2022.31% to $549.8 million in 2014, then crashed by 72.95% to $148.7 million in 2015, then tumbled by 257.16% to -$233.7 million in 2016, then plummeted by 63.03% to -$381.0 million in 2017.
  • Its last three reported values are -$381.0 million in Q4 2017, -$233.7 million for Q4 2016, and $148.7 million during Q4 2015.